Quantcast
Environmental News for a Healthier Planet and Life

Moderna Announces Promising Coronavirus Vaccine Trials

Health + Wellness
Moderna Announces Promising Coronavirus Vaccine Trials
Scientist Xinhua Yan works in Moderna's lab in Cambridge, Massachusetts on Feb. 28, 2020. David L. Ryan / The Boston Globe via Getty Images

A coronavirus vaccine tested on human volunteers appears to be safe and produce antibodies against the virus, Cambridge, Massachusetts-based biotech company Moderna announced Monday.


The promising results are from Phase 1 of a clinical trial led by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH). They have not been peer reviewed, and the vaccine now has to pass on to further tests of more people. But Moderna chief medical officer Dr. Tal Zaks told CNN that, if those studies go well, it could be ready by January 2021.

"This is absolutely good news and news that we think many have been waiting for for quite some time," Zaks said.

The trial tested 45 people aged 18 to 55, according to Moderna and CNBC. Three groups of 15 received either a 25, 100 or 250 microgram dose two times, around 28 days apart. Participants who received the lowest dose produced antibodies comparable to those produced by people who recover from the virus, while those who received the medium dose produced substantially more antibodies than recovered COVID-19 patients.

What's more, the first eight participants to receive the low and medium doses produced neutralizing antibodies at levels comparable to people who have recovered from COVID-19. These are the kinds of antibodies that actually bind the virus and stop it from attacking other cells, CNN explained.

Data on neutralizing antibodies for the rest of the participants and any data for the highest dose was not yet available, according to CNBC.

So far, reported side effects have been mild. One of the volunteers in the low and medium dose groups experienced redness and soreness at the injection site on their arm, The New York Times reported. In the high dose group, three participants experienced headaches, muscle aches and fevers that dissipated after a day. However, Zaks said the high dose would no longer be studied. This has less to do with its side effects than the fact that it is not needed to stimulate an immune response.

"The lower the dose, the more vaccine we'll be able to make," Zaks told The New York Times. "Demand is going to far outstrip supply so I think there is an ethical obligation to go with the lowest dose you can so you can make as much vaccine as possible."

Moderna's vaccine is one of more than 100 in development and one of eight being tested on humans, but it is the first to release data on a human trial, according to CNBC. It is necessary to develop multiple vaccines, The New York Times explained, because global demand is likely to far exceed what any one company can produce.

So far, the new coronavirus has sickened more than 4.8 million people worldwide and killed 318,833, according to Tuesday morning figures from Johns Hopkins University. It has also caused global economic fallout as countries around the world have locked down to prevent its spread, and news of the vaccine helped Wall Street to have its best day in weeks Monday, according to The New York Times.

The Moderna vaccine, officially called mRNA-1273, uses genetic material called messenger RNA (mRNA). The New York Times explained how it works:

The idea behind Moderna's vaccine is to inject the mRNA for part of the spike protein and have it slip into the cells of a healthy person, which then follow its instruction and crank out the viral protein. That protein should act as a red flag for the immune system, stimulating it to produce antibodies that will prevent infection by blocking the action of the spike if the person is exposed to the virus.

Moderna has several mRNA vaccines in development, but none have yet gone on the market.

However, there is a broader question of how useful any vaccine will be against the new coronavirus, since scientists don't yet know if a person who recovers from the virus is immune from getting it again, and therefore whether a vaccine will work.

"[T]he truth is, we don't know that yet," Zaks told CNN. "We are going to have to conduct formal efficacy trials where you vaccinate many, many people, and then you monitor them in the ensuing months to make sure they don't get sick."

Fossil fuel companies received $110 billion in direct and indirect financial assistance during the coronavirus pandemic, including up to $15.2 billion in direct federal relief. Andrew Hart /

By Bret Wilkins

In a year in which the United States has already suffered 16 climate-driven extreme weather events causing more than $1 billion in economic damages, and as millions of American workers face loss of essential unemployment benefits due to congressional inaction, a report published Monday reveals the Trump administration has given fossil fuel companies as much as $15.2 billion in direct relief — and tens of billions more indirectly — through federal COVID-19 recovery programs since March.

Read More Show Less

EcoWatch Daily Newsletter

Flint corn is an example of pre-contact food. Elenathewise / Getty Images

By Ashia Aubourg

As Thanksgiving approaches, some Indigenous organizations and activists caution against perpetuating further injustices towards Native communities. Indigenous activist Mariah Gladstone, for example, encourages eaters to celebrate the harvest time in ways that do not involve stereotypes and pilgrim stories.

Read More Show Less

Trending

A sign indicates that glyphosate has been used on a farmer's field. Jo Zimny / Flickr

More than half the bacteria in the human gut microbiome are sensitive to glyphosate, the mostly commonly used herbicide in the world, reported scientists this month in the Journal of Hazardous Materials.

Read More Show Less
Former U.S. Secretary of State John Kerry is seen on October 19, 2015 in Madrid, Spain. Denis Doyle / Getty Images

President-elect Joe Biden announced Monday that former Secretary of State John Kerry will sit on his National Security Council (NSC) as Special Presidential Envoy for Climate.

Read More Show Less
Susanna Pershern / Submerged Resources Center/ National Park Service / public domain

By Melissa Gaskill

Two decades ago scientists and volunteers along the Virginia coast started tossing seagrass seeds into barren seaside lagoons. Disease and an intense hurricane had wiped out the plants in the 1930s, and no nearby meadows could serve as a naturally dispersing source of seeds to bring them back.

Read More Show Less